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Post-translational modiﬁcationsIn mammals, the linker histone H1, involved in DNA packaging into chromatin, is represented by a
family of variants. H1 tails undergo post-translational modiﬁcations (PTMs) that can be detected by
mass spectrometry. We developed antibodies to analyze several of these as yet unexplored PTMs
including the combination of H1.4 K26 acetylation or trimethylation and S27 phosphorylation.
H1.2-T165 phosphorylation was detected at S and G2/M phases of the cell cycle and was dispensable
for chromatin binding and cell proliferation; while the H1.4-K26 residue was essential for proper
cell cycle progression. We conclude that histone H1 PTMs are dynamic over the cell cycle and that
the recognition of modiﬁed lysines may be affected by phosphorylation of adjacent residues.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The nucleosome core, which consists of 146 bp of DNA wrapped
around an octamer of core histones, is the fundamental subunit of
chromatin. In addition, histone H1 protein binds to linker DNA
between two nucleosomes helping stabilize the chromatin ﬁber.
In mammals, the H1 family includes up to eleven H1 variants that
are either ubiquitous or tissue-speciﬁc. The reason for this remains
unclear, but both their evolutionary conservation and signiﬁcant
differences in their amino acid sequence suggest that they are
not functionally equivalent [1,2]. Given its role in the formation
of higher-order chromatin structures, H1 has been classically seen
as a structural component related to chromatin compaction. How-
ever, in recent years, the view that H1 plays a more dynamic role in
regulating gene expression is gaining strength in the ﬁeld, mostlydue to H1 knock-out or knock-down studies in several organisms
[3–8].
Among H1 variants, there are seven somatic H1 histones in
human cells: H1.1 to H1.5 are expressed in a replication-depen-
dent manner, whereas H1.0 and H1X are replication-independent.
H1.1 is restricted to certain tissues, H1.0 accumulates in terminally
differentiated cells, and the rest are ubiquitously expressed. H1
histones are lysine-rich proteins presenting three domains: a short
basic N-terminal tail, a highly conserved central globular domain
and a long positively-charged C-terminal tail. The chromatin bind-
ing afﬁnity and residence time is different between H1 subtypes
due to differences mainly in the C-terminal tail, but also in the
N-terminal tail [9–11].
Like core histones, linker histone H1 is post-translationally
modiﬁed. According to the ‘histone code’ hypothesis, histone
post-translational modiﬁcations (PTMs) provide tools for altering
chromatin structure, either modifying electrostatic interactions
DNA-histones or allowing recruitment of chromatin modifying
enzymes [12]. With the development of mass spectrometry meth-
ods, some attempts to map H1 PTMs have been made in various
species, showing that H1 is modiﬁed mainly by phosphorylation,
but also by acetylation, methylation, ubiquitination, formylation
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tions with partners and could explain some reported speciﬁc func-
tions of H1 variants. Only some of the aforementioned histone H1
PTMs have been further analyzed in vivo.
Phosphorylation is the most well characterized modiﬁcation of
H1 histone and is tightly coupled to the cell cycle. The level of H1
phosphorylation progressively increases during the S phase,
reaches its maximum from the late G2 phase into mitosis, and
decreases rapidly in the telophase. Serine and threonine residues
in both N- and C-terminal tails are phosphorylated by cyclin-
dependent kinases (CDKs) through the recognition of the (S/T)-P-
X-(K/R) motif [13,20]. H1 phosphorylation in S phase promotes
the DNA decondensation needed for replication, while phosphory-
lation in G2/M is involved in mitotic chromosome condensation. It
has also been demonstrated that different H1.5 residues are phos-
phorylated at different cell cycle phases [21]. Furthermore, H1 is
also phosphorylated by kinases other than CDKs. For instance,
H1.4-S27, H1.4-S35 and H1.5-T10 phosphorylations are catalyzed
by Aurora B kinase, protein kinase A (PKA), and glycogen synthase
kinase-3 (GSK-3), respectively [22–24]. Interestingly, signiﬁcantly
higher levels of phosphorylated H1 have been observed in high-
grade invasive bladder cancer cells compared with normal human
bladder epithelial cells, in accordance with the greater prolifera-
tion capacity of cancer cells [25]. In agreement with the presence
of H1 phosphorylation in the interphase nucleus, H1 phosphoryla-
tion is also involved in gene regulation. For instance, H1 is phos-
phorylated before being displaced from the mouse mammary
tumor virus promoter upon hormone induction [26]. Moreover,
site-speciﬁc phosphorylation of histone H1 facilitates transcription
by RNA polymerase I and II and has been implicated in ribosome
biogenesis and control of cell growth [27].
H1 phosphorylation, together with methylation and acetylation,
is also involved in heterochromatin formation by regulating HP1
binding. Lysine residue K26 on H1.4 is known to be both methyl-
ated and acetylated. G9a histone lysine methyltransferase medi-
ates mono- and di-methylation, whereas JMJD2 reverses this
modiﬁcation [28]. Thus, HP1 binds speciﬁcally to methylated
H1.4-K26, but the interaction is regulated by a ‘phospho-switch’
on the adjacent H1.4-S27 phosphorylation sites, and this prevents
HP1 binding [29]. Moreover, histone deacetylase SirT1 interacts
with H1 and deacetylates H1.4 at K26, regulating the formation
of repressive heterochromatin [30]. Interestingly, G9a and Glp1
are also able to methylate H1.2-K187, but this methylation, which
is stable during the cell cycle, cannot recruit HP1 and it is not
reversed by JMJD2D [31].
Moreover, Kamieniarz et al. showed that H1.4-K34 acetylation
by GCN5 is associated with promoters of active genes and regula-
tory regions. This modiﬁcation seems to positively regulate tran-
scription, both by increasing H1 mobility and by recruiting
transcription factors [32]. Finally, histone H1 is also PARylated as
a result of poly ADP-ribose polymerase (PARP-1) activity mediating
H1 displacement from promoters and, consequently, leading to
chromatin remodeling and transcription activation. In fact, PARP-
1 and H1 are mutually exclusive in active promoters [33–36].
These observations favor the view that speciﬁc modiﬁcations in
linker H1 subtypes lead to them having speciﬁc functions in differ-
ent processes. Thus, we decided to develop antibodies speciﬁcally
recognizing some of the as yet uncharacterized H1 PTMs, among
others: K17 acetylation, K26-S27 single and double modiﬁcations
(acetylation or trimethylation, and phosphorylation), K46 ubiquiti-
nation and T165 phosphorylation, and we investigated the dynam-
ics of these newly-described histone H1 PTMs. Recognition of all
the modiﬁcations changed during the cell cycle due to the phos-
phorylation of Ser- or Thr-speciﬁc residues over the course of
DNA replication and mitosis. As a consequence, the recognition
intensity of neighboring acetylated or methylated Lys residues byspeciﬁc antibodies decreased. We also investigated whether K26
and T165 residues were required for cell proliferation and proper
loading of H1.4 and H1.2, respectively, onto chromatin. Expression
of a K26A mutant of H1.4 affected cell proliferation, gene expres-
sion and H1.4 stabilization in heterochromatin. Instead, H1.2-
T165A showed no differences with respect to wild-type (WT)
H1.2. Finally, H1.2-T165 phosphorylation was found to be a marker
for proliferation and cancer malignancy.2. Materials and methods
2.1. Cell lines, mutagenesis and culture conditions
Experiments were performed in the breast cancer-derived
T47D-MTVL cell line or HeLa cells, or its derivative cells stably
expressing hemagglutinin (HA)-tagged H1 variants (H1-HA), or
inducible shRNAs against H1 variants, described previously [7].
The mutagenesis of H1-HA was performed with the QuikChange
Lightning Site-Directed Mutagenesis Kit (Agilent). T47D and HeLa
cells were grown in RPMI 1640 medium and DMEM, respectively,
supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicil-
lin, and 100 lg/ml streptomycin. Colcemid (Sigma) was added at
50 ng/ml when indicated, and doxycycline (Sigma) was added at
2.5 mg/ml. Colon cancer cell lines HCT116, SW48, SW480, HCT15,
LS147T, LS180 and Caco2 were grown in DMEM with 10% FBS
(except for Caco2 for which 20% FBS was used).
2.2. Cell cycle and proliferation analysis
For cell cycle analysis, the cells were washed with cold PBS 1,
ﬁxed in 70% ethanol and stained with a solution containing 3%
Ribonuclease A (10 mg/ml, Sigma) and 3% solution A (38 mM
sodium citrate, 500 lg/ml propidium iodide) in PBS 1. Then, the
samples were analyzed by ﬂuorescence-activated cell sorting
(FACS) using a FACS Calibur machine (BD Biosciences), CellQuest
analysis software and the ModFit program. For cell proliferation
analysis, the cells of interest expressing HA-tagged H1 (GFP-posi-
tive) were mixed 1:1 with parental cells (GFP-negative) and cul-
tured. Every 3 days, the cells were split and the percentage of
cells that were GFP-positive was measured by FACS.
2.3. Histone H1 extraction, gel electrophoresis and immunoblotting
Histone H1 was puriﬁed with a 5% perchloric acid solution for
1 h at 4 C. Soluble acid proteins were precipitated with 30% tri-
chloroacetic acid overnight at 4 C, washed twice with 0.5 ml of
acetone and reconstituted in water. Protein concentration was
determined with the Micro BCA protein assay (Pierce). The puriﬁed
histones were separated by 10% SDS–PAGE, transferred to a polyvi-
nylidene diﬂuoride (PVDF) membrane, blocked with Odyssey
blocking buffer (LI-COR Biosciences) for 1 h, and incubated with
primary antibodies overnight at 4 C and with secondary antibod-
ies conjugated to ﬂuorescent dye (IRDye 680 goat anti-rabbit IgG,
Li-Cor) for 1 h at room temperature. Then, the bands were visual-
ized and quantiﬁed in an Odyssey Infrared Imaging System. All
the polyclonal antibodies speciﬁcally recognizing human H1 PTMs
that are described here were produced on request by Abcam or
Millipore by rabbit immunizations with the peptides indicated in
Table 1. Other antibodies used in this study, including histone H1
variant speciﬁc antibodies generated in our laboratory, are avail-
able from Abcam: H1.0 (ab11079), H1.2 (ab17677), H1.3
(ab24174), H1.5 (ab24175), H1-T18P (ab3595), H1.4-T146P
(ab3596), EZH2 (ab51605), Suv39H (ab12405), and HA (ab9110).
Total H1 antibody was from Millipore (05-457). HP1b was from
Euromedex (1MOD-1A9-AS).
Table 1
Antibodies recognizing histone H1 post-translational modiﬁcations.
PTM H1 variant
(PTM)a
Immunizing peptide H1 variant
(peptide)b
Source Catalog No. Addit. PTMsc
K17 acetyl 2, 3, 4, 5 AAPAPAE(acK)TP 4 Millipore NA T18ph
K26 acetyl 4 AR(acK)SAGAAKRK 4 Millipore NA S27ph, K34ac
K26 trimethyl 4 VKKKAR(3meK)SAGAA 4 Abcam NA S27ph
S27 phospho 4 VKKKARK(pS)AGAA 4 Abcam NA K26me/ac
K26 acetyl/S27 phospho 4 AR(acK)(pS)AGAAKRK 4 Millipore 06-1372 K34ac
K26 trimethyl/S27 phospho 4 VKKKAR(3meK)(pS)AGAA 4 Abcam ab33231 –
K46 ubiquitin 2, 3, 4 IT(ubK)AVAASK 2, 3, 4, 5 Millipore NA K52ac
T165 phospho 2 AA(pT)VTKKVAK 2 Millipore 06-1370 K168ac
NA, not currently available.
a H1 variants where the indicated PTM has been described in the Garcia et al. or Wisniewski et al. reports.
b H1 variants where the designed immunizing peptides share 100% sequence identity.
c Residues present in the immunizing peptides that can receive additional PTMs according to the reports indicated above.
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Puriﬁed H1 histones were incubated for 30 min at 30 C with
recombinant Lambda Protein Phosphatase (New England BioLabs)
at 5–100 Units in a 50-ll reaction volume containing 50 mM
HEPES, 100 mM NaCl, 2 mM DTT, 0.01% Brij 35, pH 7.5 and 1 mM
MnCl2. The reaction was stopped by heat inactivation after the
addition of gel electrophoresis loading buffer and H1 was resolved
in SDS–PAGE for immunoblotting.
2.5. Chromatin immunoprecipitation (ChIP)
ChIP was performed according to the Upstate-Millipore stan-
dard protocol. Brieﬂy, cells were ﬁxed using 1% formaldehyde, har-
vested and sonicated to generate chromatin fragments between
200 and 500 bp. The sheared chromatin was immunoprecipitated
overnight using 2 lg of antibody against HA. The immunocom-
plexes were recovered using a mix of protein A and protein G
Sepharose, washed and eluted. The cross-linking was reversed at
65 C overnight and immunoprecipitated DNA was recovered using
the PCR Puriﬁcation Kit from Qiagen. The presence of the genomic
regions of interests was checked by real-time PCR, which was per-
formed on ChIP and input DNA using EXPRESS SYBR GreenER qPCR
SuperMix Universal (Invitrogen) and speciﬁc oligonucleotides in a
Roche 480 LightCycler. ChIP values were corrected for their corre-
sponding input chromatin sample. All oligonucleotide sequences
used for the ampliﬁcations are available upon request.
2.6. Immunoprecipitation
Nuclear extracts were prepared by sonication of nuclei in
10 mM HEPES (pH 7.9), 2.25 lM MgCl2, 20% (vol/vol) glycerol,
0.1 mM EDTA, 0.1% Nonidet P-40, 1 M NaCl. Supernatant was dia-
lyzed in BC200 buffer: 25 mM Tris (pH 7.9), 10% (vol/vol) glycerol,
0.2 mM EDTA, 200 mM KCl). For immunoprecipitations, nuclear
extracts adjusted to equal protein concentrations were incubated
for 2 h with antibodies. Protein A beads were then added to the
mixes, which were further incubated for 1 h. Beads were collected
by centrifugation and washed three times in BC200 buffer. Proteins
were eluted in 2 SDS sample buffer at 80 C for 10 min.
2.7. Puriﬁcation and infrared spectroscopy of human H1.2 and its
mutants
HA-tagged H1.2 and its mutants, T165A and T165E, were
cloned into pEV21a generating histidine tagging, and these vec-
tors transformed into Escherichia coli BL21 (DE3). Recombinant
proteins were expressed and puriﬁed by metal-afﬁnity chroma-
tography as previously described [37]. Then, the buffer wasexchanged and the recombinant proteins were digested with car-
boxypeptidase A (Type II-PMSF treated) in the conditions speci-
ﬁed by the manufacturer (Sigma) to remove the His6-tag. The
proteins were further puriﬁed by hydroxyapatite chromatogra-
phy on a CHT-II cartridge (Bio-Rad) as previously described
[38]. Finally, the proteins were desalted by gel ﬁltration through
Sephadex G-25 (Amersham Biosciences) and lyophilized. FTIR
spectra of human histone H1.2 and its mutants were measured
at 5 mg/ml in 10 mM HEPES (pH 7.0) plus 140 mM NaCl in
D2O medium. Measurements were performed on an FT600 Bio-
Rad spectrometer equipped with an MCT detector, using a
demountable liquid cell with calcium ﬂuoride windows and
50-lm spacers. Typically, 1000 scans were performed for each
background and sample, and the spectra were obtained with a
nominal resolution of 2 cm1, at 22 C. DNA–protein complexes
contained the appropriate amount of DNA for each protein/
DNA ratio (w/w). The DNA contribution to the spectra of the
complexes with the H1.2 species was subtracted as described
elsewhere [39]. Data treatment and band decomposition of the
original amide I0 band were performed as previously described
using GRAMS 9.0 software [40].
2.8. RNA extraction, reverse transcriptase PCR and microarrays
Total RNA was extracted using a High Pure RNA Isolation Kit
(Roche) according to the manufacturer’s instructions, and the
cDNA was obtained from 100 ng of total RNA using a SuperScript
VILO cDNA synthesis Kit (Invitrogen). The real-time PCRs were per-
formed using EXPRESS SYBR GreenER qPCR SuperMix Universal
(Invitrogen) and speciﬁc oligonucleotides in a Roche 480 Light-
Cycler. The procedures for microarray hybridization using an Illu-
mina platform (GPL6883 Illumina HumanRef-8 v3.0 Expression
BeadChip) and data analysis are described elsewhere [7]. Gene
ontology analysis was performed using the Gene Set Enrichment
Analysis (GSEA) program. Microarray data sets are available in
the Gene Expression Omnibus (GEO) database under the accession
number GSE55786.
3. Results
In order to study the dynamics of histone H1 PTMs in cultured
human cells, we developed polyclonal antibodies speciﬁcally
recognizing someof theH1PTMsdescribedelsewherebymass spec-
trometry analysis [6,7] namely: K17 acetylation (K17-Acet), K26
acetylation/S27phosphorylation (K26-Acet/S27-P), K26 trimethyla-
tion/S27 phosphorylation (K26-Met/S27-P), K46 ubiquitination
(K46-Ub), and T165phosphorylation (T165-P) (Table 1). All the anti-
bodies were obtained by standard procedures and their speciﬁcities
were evaluated by dot blot (see Supplementary data, S1).
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breast cancer cell line either untreated or treated with Colcemid
to induce cell cycle arrest in mitosis. Histone H1 proteins were
then extracted and analyzed by Western blot (Fig. 1). The level of
H1 acetylation on K17 decreased upon accumulation of cells in
mitosis, while the adjacent CDK-mediated T18 phosphorylation
increased. We established that the H1 variant speciﬁcally recog-
nized by the K17-Acet antibody was H1.4 by immunoprecipitationFig. 1. Histone H1 PTMs are dynamic over the cell cycle. Histone H1 was extracted
from T47D cells treated or not with Colcemid (50 ng/ml) overnight, resolved in
SDS–PAGE, and immunoblotted with antibodies speciﬁcally recognizing human
H1.0 or histone H1 PTMs.of stably-expressed H1.4-HA followed by immunoblotting and by
depletion of the endogenous H1.4 (see Supplementary data, S2A
and B), in agreement with the peptide sequence used for generat-
ing this antibody. H1 ubiquitination on K46 also decreased during
G2/M arrest and the signal almost disappeared upon knock-down
of H1.5 indicating that it may be the variant harboring this modi-
ﬁcation in cultured T47D cells, despite the peptide used for rabbit
immunization being common to four somatic H1 variants (Fig. 1)
(see Supplementary data, S2C).
Then, we analyzed phosphorylation on T165, which increased
upon Colcemid-induced mitosis arrest (Fig. 1). T165 phosphoryla-
tion was speciﬁc for the H1.2 variant as shown by both immuno-
precipitation of stably expressed H1.2-HA (Fig. 2A and
Supplementary data, S3A), and depletion of the endogenous H1.2
(Fig. 2B). T165-P of H1.2 at mitosis was also seen in HeLa cells
(Fig. 2C). Moreover, the antibody was speciﬁc for the phosphory-
lated residue as the hybridization signal disappeared upon phos-
phatase treatment of puriﬁed H1 (Fig. 2D and Supplementary
data, S3B).
Release of cultured cells from a double thymidine block
revealed that H1.2 T165 phosphorylation occurred parallel to
phosphorylation of H1.4 T146, a known CDK target site (Fig. 3A).
In HeLa cells, 6 h after the double thymidine block release, most
cells were in S phase, while T165 and T146 residues appeared to
be phosphorylated and remained in this state when the cells
moved to G2/M. In T47D cells, there was a low rate of transition
to the S phase and the phosphorylation increased at 8 h coinciding
with a peak in the number of cells in G2/M. This suggests that H1.2
T165 is phosphorylated during replication and mitosis, similar to
other H1 residues targeted by CDKs. Nonetheless, T165 is not
within a CDK recognition motif and its phosphorylation was unaf-
fected by the CDK inhibitor roscovitine (see Supplementary data,
S4). The KinasePhos web tool [41] predicted T165 to be in a protein
kinase C (PKC) recognition motif but T165-P was not affected by
the PKC inhibitor GF109203X either. Similarly, it was unaltered
by inhibitors of other candidate kinases, namely Aurora, PI3K,
pTEF-b and PKA, it remaining unclear which enzyme is responsible
for the phosphorylation in this case (see Supplementary data, S4
and data not shown).
At this point, we have identiﬁed the presence of H1.2 T165
phosphorylation in breast (T47D) and cervical (HeLa) cancer cell
lines. Next, we explored whether the phosphorylation of H1.2
T165 also occurred in several colon cancer cell lines and, if so,
whether there were differences between cell lines derived from
low- or high-grade cancers. T165-P was detected and was more
intense in cells derived from high-grade cancers, similar to H1.4
T146-P (Fig. 3B). As high-grade cancer cells are more proliferative,
this ﬁnding indicates that both modiﬁcations may serve as prolif-
eration markers for cancer diagnosis. In addition, H1.3 was absent
in the cell lines derived from higher-grade primary tumors, sug-
gesting that not only PTMs but also H1 variants abundance may
differ over the course of tumor progression.
In order to investigate the dispensability of T165 and its phos-
phorylation, this residue was substituted by Ala and Glu within a
stably expressing hemagglutinin-tagged H1.2 (H1.2-HA) in T47D
cells in order to inhibit or mimic this phosphorylation (H1.2-
T165A and H1.2-T165E), respectively (see Supplementary data,
S5A). Mutations of this T165 residue had no apparent effect on pro-
liferation and the cell cycle, on H1.2 binding to chromatin (see Sup-
plementary data, S5B and C), or on the global structure of the
mutated proteins compared with the WT as judged by infrared
spectroscopy on recombinant H1.2 in the presence or not of DNA
(see Supplementary data, Table S1). As predicted, the T165-P anti-
body was unable to recognize H1.2-T165A, but constitutively rec-
ognized H1.2-T165E (see Supplementary data, S5D). ChIP of
H1.2-HA showed that this variant bound to active and repressed
Fig. 2. The T165-P antibody is speciﬁc for H1.2. (A) Immunoblot of H1.2-T165-P after H1.2 immunoprecipitation. H1.2-HA was immunoprecipitated with an anti-HA
antibody, or IgG as a control, from nuclear extracts of cells stably expressing H1.2-HA, and blotted with the indicated antibodies. (B) Immunoblot of H1.2-T165-P after H1.2
depletion. T47D derivative cells stably infected with a lentiviral inducible system for the expression of shRNA against H1.2 (H1.2 KD) were treated for 6 days with doxycycline
or left untreated. Colcemid was added 4 h prior to H1 extraction where indicated. H1 extracts were analyzed by immunoblot against H1.2-T165-P, H1.2 or H1.5 as a loading
control. (C) HeLa cells harboring the inducible shRNA against H1.2 or a control random shRNA were treated and analyzed as in (B). Coomassie staining of H1 PAGE is shown as
a loading control. (D) Immunoblot of H1.2-T165-P after phosphatase treatment. H1 was extracted from T47D cells treated or not with Colcemid overnight, incubated with
increasing concentrations of Lambda Protein Phosphatase for 30 min and immunoblotted with H1.2-T165-P antibody. Coomassie staining and H1.0 immunoblot are shown as
loading controls.
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ences between the mutated and the WT forms of H1.2 (Fig. 4).
Active genes (CDK2, JUN), but not repressed genes (NANOG),
showed local H1.2 (WT or mutant) depletion at the transcription
start sites (TSS) compared with the corresponding upstream pro-
moter region, as described elsewhere [33,42].
Additionally, we designed several antibodies speciﬁcally recog-
nizing the acetylated or trimethylated form of H1.4-K26, alone or
in combination with H1.4-S27 phosphorylation. The antibodies
recognizing the K26-3Met and K26-Acet alone cannot detect these
modiﬁcations when the adjacent serine (S27) is phosphorylated, as
shown by dot blot analysis (see Supplementary data, S1).
Conversely, the antibodies K26-Met/S27-P and K26-Acet/S27-P
can only detect K26 modiﬁcations in the presence of S27-P.
Accordingly, Colcemid treatment, predicted to increase H1.4-S27
phosphorylation, resulted in a lower level of detection of K26-
3Met and K26-Acet by antibodies raised against these singlemodiﬁcations, whereas there was a higher level of detection with
the antibodies against double modiﬁcations, suggesting a switch
from mono- to bi-modiﬁed H1.4 K26-S27 residues (Fig. 1).
Antibody binding decreased upon H1.4 knock-down in T47D
and HeLa cells, as well as upon phosphatase treatment of puriﬁed
H1, demonstrating its H1.4 variant and phospho-speciﬁcity (see
Supplementary data, S6). The release of cultured T47D cells from
a double thymidine block revealed that bi-modiﬁed K26-S27
increased at G2/M (8 h after release), as did single S27 phosphory-
lation, while single K26 trimethylation decreased (Fig. 5A and Sup-
plementary data, S7). Interestingly, in HeLa cells K26-Met/S27-P
did not accumulate in S phase as occurred for H1.4 T146 and
H1.2 T165 phosphorylation (Fig. 3A).
Considering the reported role of the H1.4-K26 residue in
recruiting HP1 proteins, we then decided to mutate this residue
and compare the growth of T47D cell lines stably expressing HA-
tagged H1.4 WT with K26A. The H1.4-K26A mutation led to a
Fig. 3. H1.2 T165-P occurs at S and G2/M phases of the cell cycle and marks highly proliferative cancer cells. (A) Analysis of H1 phosphorylation after release from double-
thymidine block. HeLa or T47D cells were arrested at the beginning of the S phase using a double thymidine block. After release for different times, cells were harvested to
perform cell cycle analysis by ﬂuorescence-activated cell sorting (FACS) after propidium iodide staining, and H1 extraction. Immunoblot was performed with the indicated H1
phospho-speciﬁc antibodies. H1.2 blotting and Coomassie staining were used as loading controls. Graphs with band density quantiﬁcation are shown in Supplementary data,
S7C. The upper graphs represent the percentage of cells in G1, S and G2/M phases as established by FACS. (B) H1.2 T165-P in colon cancer cell lines at different stages of
malignancy. H1 was extracted from seven different colon cancer cell lines growing exponentially and immunoblotted against the indicated antibodies. Colon cancer cell lines
are ordered by origin from high- to low-grade malignancy and proliferation rate. HCT116 (1; grade D), SW48 (2; grade IV), SW480 (3; grade III–IV), HCT15 (4; grade C), LS147T
(5; grade B), LS180 (6; grade B), and Caco2 (7; grade I). Grades A–D (Dukes’ classiﬁcation), or I–IV, from low to high malignancy, are indicated. Coomassie staining was used as
loading control; notice that LS180 was overloaded. Relative band density quantiﬁcation for each antibody respect to H1.2 (Pearson’s R correlation coefﬁcient between H1.2
and Coomassie was 0.95) and relative to the maximal value is shown on the right panels.
2358 J.-M. Terme et al. / FEBS Letters 588 (2014) 2353–2362
Fig. 4. The T165 residue is dispensable for proper H1.2 loading onto chromatin. Cross-linked chromatin from T47D cells stably expressing H1.2-HA WT, T165A or T165E was
used for ChIP experiments with an anti-HA antibody or IgG as control. The precipitated DNA fragments were used for qPCR with primers for the indicated regions of CDK2,
JUN and NANOG genes (upstream promoter, TSS and within the coding region), and for the repetitive satellite regions SAT2 and SATa. CDK2 and JUN represent active genes in
T47D cells, while NANOG is repressed. The coding region of NANOG was not assessed. Ampliﬁcation of input DNA (representing 1% of immunoprecipitated DNA) was used for
normalization. The means and SDs are shown for a representative experiment quantiﬁed in triplicate. Signiﬁcance between H1 mutant data sets was tested using the
Student’s t-test (⁄P-value <0.05; ⁄⁄P-value <0.01; ns, no signiﬁcance).
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possibly due to G2/M arrest (Fig. 5B and C and Supplementary data,
S8). In chromatin extracts, we veriﬁed that both H1.4-WT and
K26A are equally well incorporated into chromatin (Fig. 5D). Inter-
estingly, the presence of H1.4-K26A in chromatin was associated
with lower levels of H1.4 partners which are known to bind this
residue, i.e., HP1b and EZH2 (Fig. 5D and Supplementary data,
S9). Furthermore, the H1.4-K26A mutant was less well stabilized
in heterochromatin satellite regions, as shown by ChIP (Fig. 5E
and Supplementary data, S10).
In order to investigate whether the potential modiﬁcations of
H1.4-K26 play a role in gene expression control, we compared glo-
bal gene expression of H1.4-WT and K26A over-expressing cell
lines using microarrays. The expression of both proteins produced
both up- and down-regulation of some genes compared with levels
in control cells. Most genes deregulated upon H1.4-WT expression
were also affected in K26A expressing cells, but around 19%
depended on K26 integrity (Fig. 5F and Supplementary data,
Table S2). Interestingly, K26A expression deregulated approxi-
mately twice as many genes as H1.4-WT, maybe due to the prolif-
eration defect in K26A cells. In relation to this, ontology analysis of
genes differentially expressed in H1.4-WT and K26A cells using the
GSEA program revealed changes in biological functions related to
the cell cycle and DNA metabolism (see Supplementary data,
Table S3). Further evidence that H1.4 levels may inﬂuence gene
expression came from the observation that some of the genes
up- or down-regulated upon H1.4 overexpression were deregu-
lated in the opposite sense upon H1.4 knockdown, mainly genes
repressed by H1.4 such as CDC20B or ROPN1L (see Supplementary
data, S11).
To test if the genes found to be differentially expressed upon
H1.4 expression that depended on K26 are normally enriched/
depleted for H1.4 we took our ChIP-seq data on H1.4-HAdistribution [42] and look at the number of enriched and depleted
islands on those genes compared to random samples of the same
number of genes (see Supplementary data, S12). Although up-reg-
ulated genes presented more H1.4 (and other H1 variants, data not
shown) enrichment islands and less depletion islands than random
genes, P-values indicated that this was not signiﬁcant. Similarly,
down-regulated genes presented non-signiﬁcant reduced numbers
of enrichment islands, but average number of depletion islands. In
conclusion, no evidences yet point towards the notion that the sub-
set of genes deregulated upon depletion or overexpression of a par-
ticular H1 variant are speciﬁcally enriched on such variant.
4. Discussion
Depletion experiments of individual H1 variants in cultured
cells have shown that distinct small subsets of genes are regulated
by each variant and different phenotypes are produced [7]. Histone
variant-speciﬁc PTMs could account for differential effects of the
accumulation or depletion of distinct variants. Moreover, PTMs
may be dynamic, adapting to cell cycle progression or responding
to external stimuli or to the activation of a variety of signaling
pathways. One of the consequences of the H1 variant PTMs may
be an alteration of the interaction between histones and DNA, or
between histones and chromatin-associated proteins.
Post-translational modiﬁcations of core histones, in particular
H3 and H4, have been extensively studied and are the basis for
the so-called ‘histone code’ involved in the regulation of genome
functions including gene expression control. By contrast, little is
known about linker histone PTMs. Few modiﬁcations, mostly
CDK-dependent Ser and Thr phosphorylations, were investigated
before two reports described the identiﬁcation of new histone H1
PTMs by mass spectrometry analysis [13,14]. The historical difﬁ-
culty of obtaining good antibodies against H1 variants or their
Fig. 5. The H1.4-K26 residue is required for proper cell proliferation and stabilization in heterochromatin. (A) H1.4 S27-P occurs at the G2/M phase of the cell cycle. T47D cells
were arrested at the beginning of S phase using a double thymidine block. Upon release at different times, cells were harvested to perform cell cycle analysis by FACS after
propidium iodide staining, and H1 extraction. Immunoblot was performed with the indicated H1.4 antibodies. H1.0 blotting was performed as a loading control. The upper
graphs represent the percentage of cells in G1, S and G2/M phases as established by FACS. Graph with band density quantiﬁcation is shown in Supplementary data, S7B. (B)
Expression of H1.4-K26A impairs cell proliferation. Both H1.4-HA WT and K26A stably expressing cell lines (GFP-positive) were mixed 1:1 with parental T47D cells (GFP-
negative). Every 3 days, cells were split and the percentage of GFP-positive cells measured by ﬂuorescence-activated cell sorting. Data are expressed as the ratio of GFP-
positive versus GFP-negative cells over time and correspond to a representative experiment performed in duplicate. (C) K26A cells accumulate in G2/M. Cell cycle proﬁle after
propidium iodide (PI) staining of H1.4-HA WT and K26A expressing cells, represented as the percentage of cells in G1, S and G2/M. Data correspond to a representative
experiment performed in duplicate. The means and SDs for four independent experiments are shown. Signiﬁcance was tested using the Student’s t-test (⁄P-value <0.05; ⁄⁄P-
value <0.01). (D) Chromatin content in H1.4-HAWT or K26A stably expressing cells. Chromatin was extracted from cells stably expressing H1.4-HAWT or K26A and analyzed
by immunoblot with the indicated antibodies. Bands were quantiﬁed and the ratio between K26A and WT is indicated. (E) Detection of histone H1.4-HA WT or K26A at
heterochromatic regions. Cross-linked chromatin from T47D cells stably expressing H1.4-HA WT or K26A was used for ChIP experiments with an anti-HA antibody. The
precipitated DNA fragments were exposed to qPCR with primers for the indicated regions. Ampliﬁcation of input DNA (representing 1% of immunoprecipitated DNA) was
used for normalization. The means and SDs are shown from a representative experiment quantiﬁed in triplicate. Signiﬁcance was tested using the Student’s t-test (⁄⁄P-value
<0.01). (F) Expression of H1.4-HA WT and K26A deregulates common and unique genes. Venn diagrams showing the number of genes up- or down-regulated with a fold
change (FC)P 1.4 in H1.4-HA WT or K26A expressing cells compared to control cells established by Illumina microarray hybridization.
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vance of such PTMs.
We have developed and tested polyclonal antibodies against
several H1 PTMs including phosphorylation, acetylation, trimethy-
lation and monoubiquitination, and also antibodies against double
modiﬁcations (Lys-acetyl/Ser-phospho or Lys-trimethyl/Ser-phos-
pho). Here we show the results with the antibodies that are able
to detect the occurrence of H1 PTMs in a breast cancer cell line.
In addition to the PTMs described above, we also tested antibodies
raised against the following modiﬁcations present in several H1
variants: K34, K46, K85 and K90 acetylations, K90 formylation,
and the double modiﬁcation K34-acet/S36-phospho (see Supple-
mentary data, S13). Those raised against acetylated Lys were spe-
ciﬁc for the modiﬁed peptide and reacted with H1 extracted
from cells in Western blot experiments, but overall were not fur-
ther characterized due to their low reactivity.
We have focused on the dynamics, histone variant speciﬁcity
and dispensability of two modiﬁed residues: H1.2 T165 phos-
phorylation and H1.4 K26 acetylation or trimethylation, and its
interplay with phosphorylation of its neighbor S27. We show that
phosphorylation of these amino acids occurs during the G2/M
phase of the cell cycle. In fact, H1.4-S27 phosphorylation by Aur-
ora B over the course of mitosis has been previously reported
[24]. While the global increase in H1 phosphorylation during
mitosis was expected, the decrease in K46-ubiquitination is more
surprising and needs further investigation. Less K26 acetylation
and trimethylation were also detected when cells accumulated
in mitosis, presumably due to S27 phosphorylation of existing
K26-unmodiﬁed, acetylated or trimethylated histone H1.4, as
the level of detection with the double-modiﬁcation antibodies
was higher. This indicates that the double modiﬁcations exist
in vivo at the same histone tail at the same time, and that anti
K26-acet or K26-trimet antibodies are unable to recognize these
modiﬁcations when a phosphate group is added to the neighbor-
ing Ser. Similarly, as proposed by the phospho-switch model, a
protein binding to modiﬁed K26 may be released when S27 is
phosphorylated [29].
Interestingly, T165-P started to accumulate in S phase, as previ-
ously reported for the CDK-dependent phosphorylation of histone
H1 at (S/T)-P-X-(K/R) motifs, suggesting that this modiﬁcation
may have a more complex role than chromosome compaction dur-
ing mitosis. H1 phosphorylation over the course of DNA replication
has been implicated in chromatin decompaction. Our attempts to
identify the kinase responsible for T165 phosphorylation have so
far been unsuccessful. It would be interesting to determine which
as yet unknown signaling pathways regulate this newly described
phosphorylation on histone H1.2, as well as its biological rele-
vance. One possibility could be that multiple kinases target H1.2
T165 redundantly. We have shown that T165-P is dispensable for
cell cycle progression and H1.2 binding to chromatin. This suggests
that T165-P may be additive to the CDK-dependent phosphoryla-
tion of other Ser and Thr residues and by itself have limited struc-
tural consequences, instead of representing a highly speciﬁc
regulatory binding site for a speciﬁc factor. Alternatively, T165-P
may be dispensable for the cell type analyzed here grown under
cell culture conditions or even completely non-functional, but
may be more relevant under other conditions.
On the other hand, here we suggest that K26 modiﬁcations are
required for proper cell proliferation and stabilization of hetero-
chromatin. The mutation of the H1.4-K26 residue has a signiﬁcant
effect on the cell cycle and gene expression, probably due to a
defect in the recruitment of histone H1 partners to chromatin.
Expression of H1.4-K26A induced both up- and down-regulation
of gene expression compared with H1.4-WT expression, consistent
with both active and repressive effects of H1.4-K26 PTMs. Very few
genes presented altered expression in opposite senses whetherH1.4 was overexpressed or knocked down, and we do not believe
that this is due to speciﬁc binding of H1.4 to these promoters, as
we have previously reported that all gene promoters are bound
by any H1 variant quite indistinctly [42]. We have shown here that
a subset of genes differentially expressed upon H1.4 overexpres-
sion do not contain signiﬁcant enrichment of this variant. Despite
ubiquitous binding of H1 variants to promoters, differential inter-
action with partners, probably mediated by variant-speciﬁc PTMs,
may explain speciﬁc participation of H1 variants to gene
expression.
We have proposed that phosphorylation of H1 residues such
as T165 in H1.2 and T146 in H1.4 may be considered proliferation
markers and, accordingly, mark tumor cells with the highest rate
of division, regularly associated with the highest level of malig-
nancy. It is likely that cell cycle-dependent phosphorylation of
certain Ser or Thr residues in the tails of H1 variants is of major
importance in determining the architecture of chromatin during
cell proliferation and differentiation. Alterations in the regulation
of H1 phosphorylation may be involved in the genetic dysregula-
tion that is fundamental to carcinogenesis. Aberrant chromatin
structure may contribute to malignant transformation and tumor
formation. Understanding the role of different H1 variants and
their modiﬁcation proﬁles may be relevant to many aspects of
cell survival, proliferation, apoptosis, differentiation and
transformation.
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